A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma
Latest Information Update: 19 Nov 2024
Price :
$35 *
At a glance
- Drugs Talimogene laherparepvec (Primary) ; Talimogene laherparepvec (Primary)
- Indications Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Soft tissue sarcoma
- Focus Adverse reactions; Therapeutic Use
- 15 Nov 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 15 Nov 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
- 05 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.